Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The Company’s segments include Pharmaceutical Services and Active Ingredients, Global Generics, and Others. The Pharmaceutical Services and Active Ingredients segment primarily consists of the Company’s business of manufacturing and marketing APIs and intermediates. The Global Generics segment consists of the Company’s business of manufacturing and marketing prescription and OTC finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
- Revenue in INR (TTM)272.13bn
- Net income in INR52.28bn
- Incorporated1984
- Employees24.83k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Menolabs LLC | 8.39% | 3.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 582.00bn | 16.87k | 37.00 | -- | 31.14 | 4.61 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 646.52bn | 15.69k | 23.35 | -- | 15.10 | 2.32 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 194.80bn | 17.91bn | 726.65bn | 18.97k | 40.69 | -- | 25.83 | 3.73 | 39.19 | 39.19 | 426.18 | -- | -- | -- | -- | 10,268,360.00 | -- | 0.2337 | -- | 0.3443 | 64.99 | 58.56 | 9.29 | 0.3673 | -- | 6.89 | -- | 470.26 | 1.44 | 1.04 | 128.15 | 11.35 | -0.7025 | -4.36 |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 911.87bn | 13.57k | 60.63 | -- | 39.66 | 8.71 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Zydus Lifesciences Ltd | 186.81bn | 29.56bn | 957.18bn | 23.03k | 32.57 | -- | 25.93 | 5.12 | 29.21 | 29.38 | 184.58 | -- | -- | -- | -- | 8,113,133.00 | -- | 7.92 | -- | 12.61 | 66.21 | 60.14 | 15.81 | 12.89 | -- | -- | -- | 20.55 | 14.08 | 7.59 | -12.34 | 1.83 | -0.3532 | 11.38 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 960.83bn | 18.47k | 55.68 | -- | 44.96 | 9.66 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Divi's Laboratories Ltd | 74.93bn | 13.83bn | 1.02tn | 16.95k | 73.77 | -- | 58.21 | 13.62 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
| Dr Reddy's Laboratories Ltd | 272.13bn | 52.28bn | 1.04tn | 24.83k | 19.82 | -- | 15.58 | 3.81 | 313.75 | 313.75 | 1,633.13 | -- | -- | -- | -- | 10,958,640.00 | -- | 9.68 | -- | 13.81 | 70.55 | 65.53 | 19.21 | 12.76 | -- | 48.92 | -- | 17.84 | 14.50 | 11.55 | 106.94 | 33.23 | 11.31 | 14.87 |
| Cipla Ltd | 253.50bn | 37.08bn | 1.14tn | 26.62k | 30.63 | -- | 23.40 | 4.48 | 45.92 | 45.92 | 313.91 | -- | -- | -- | -- | 9,524,760.00 | -- | 8.61 | -- | 10.60 | 65.16 | 57.97 | 14.77 | 11.17 | -- | 47.26 | -- | 19.05 | 4.55 | 8.38 | 11.33 | 14.71 | 7.70 | 23.16 |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 22 Nov 2023 | 9.33m | 5.59% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.97m | 2.38% |
| First Sentier Investors (Australia) IM Ltd.as of 30 Jun 2023 | 3.66m | 2.19% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 3.26m | 1.95% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 2.65m | 1.59% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 2.38m | 1.43% |
| GIC Pte Ltd. (Investment Management)as of 30 Jun 2023 | 2.07m | 1.24% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Mar 2024 | 1.60m | 0.96% |
| Geode Capital Management LLCas of 18 Apr 2024 | 1.55m | 0.93% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.54m | 0.92% |
